The benefits and risks of HRT, in numbers — not slogans.
You deserve the straight version: what hormone therapy reliably does, what it does not, and how big the risks actually are for a woman in your situation.
What HRT reliably does
Hormone therapy is the most effective treatment available for hot flashes and night sweats, treats the genitourinary syndrome of menopause, and prevents the rapid bone loss that follows the final period. In the Women's Health Initiative — the largest randomized trial of hormone therapy ever conducted — combined therapy reduced hip fractures by roughly 33% and vertebral fractures by about 35%. Hormone therapy is also associated with a roughly 30% reduction in new type 2 diabetes.
What it doesn't do
It is not an anti-aging cure, it is not used to prevent or treat dementia, and it is not used for primary or secondary prevention of cardiovascular disease. Claims that go far beyond the evidence — from any direction — get an honest appraisal here, not a sales pitch.
The breast cancer question, by regimen
The honest answer is more nuanced than the 2002 headlines or the current "all clear" social media take. Risk depends on the type of therapy, duration, the progestogen used, and your baseline risk:
| Regimen | Effect on breast cancer risk |
|---|---|
| Estrogen alone (no uterus) | Neutral or slightly reduced in randomized data; the WHI showed a non-significant reduction over 7+ years. |
| Estrogen + progestogen | Small increase that grows with duration — roughly 9 additional cases per 10,000 women per year in the WHI; comparable to risk factors like obesity, alcohol, or inactivity. |
| Micronized progesterone | Appears to carry less breast cancer risk than synthetic progestins — our preferred choice when a progestogen is needed. |
| Local vaginal estrogen | No measurable increase in risk; often usable even in breast cancer survivors, with oncology input. |
| HRT in POI (under ~51) | No increased risk above the age-adjusted general population risk. |
Clotting, stroke, and the route of delivery
Oral estrogen passes through the liver first, which raises clotting factors and triglycerides. Transdermal estrogen bypasses that first-pass effect and has a more favorable venous-thrombosis and cardiovascular profile — which is why we prefer patches or gels for women with elevated baseline risk. Risk is not one number; it is a function of formulation, dose, route, your age, and time since menopause. We quantify it for your situation rather than waving it off — in either direction.